Title: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials
Abstract: International Journal of Gynecology & ObstetricsEarly View CORRESPONDENCE Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials Muhammad Sohaib Khan, Muhammad Sohaib Khan orcid.org/0000-0002-1906-2709 Department of Medicine, Dow University of Health Sciences, Karachi, PakistanSearch for more papers by this authorSyed Muhammad Muneeb Akhtar, Syed Muhammad Muneeb Akhtar orcid.org/0009-0005-0850-9033 Department of Medicine, Dow University of Health Sciences, Karachi, PakistanSearch for more papers by this authorMuhammad Sohaib Asghar, Corresponding Author Muhammad Sohaib Asghar [email protected] orcid.org/0000-0001-6705-2030 Mayo Clinic Rochester, Rochester, Minnesota, USA Correspondence Muhammad Sohaib Asghar, Mayo Clinic Rochester, Minnesota, USA. Email: [email protected]Search for more papers by this author Muhammad Sohaib Khan, Muhammad Sohaib Khan orcid.org/0000-0002-1906-2709 Department of Medicine, Dow University of Health Sciences, Karachi, PakistanSearch for more papers by this authorSyed Muhammad Muneeb Akhtar, Syed Muhammad Muneeb Akhtar orcid.org/0009-0005-0850-9033 Department of Medicine, Dow University of Health Sciences, Karachi, PakistanSearch for more papers by this authorMuhammad Sohaib Asghar, Corresponding Author Muhammad Sohaib Asghar [email protected] orcid.org/0000-0001-6705-2030 Mayo Clinic Rochester, Rochester, Minnesota, USA Correspondence Muhammad Sohaib Asghar, Mayo Clinic Rochester, Minnesota, USA. Email: [email protected]Search for more papers by this author First published: 16 June 2024 https://doi.org/10.1002/ijgo.15741Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Akhtar SMM, Abraish A, Khan MS, et al. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Int J Gyneol Obstet. 2024; 00: 1-15. CASGoogle Scholar 2Douxfils J, Beaudart C, Dogné JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. Lancet. 2023; 402(10413): 1623-1625. doi:10.1016/S0140-6736(23)01634-3 10.1016/S0140-6736(23)01634-3 CASPubMedWeb of Science®Google Scholar 3Rahman UA, Kashif TB, Usman M, et al. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis. Medicine. 2023; 102(50):e36592. 10.1097/MD.0000000000036592 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation
Publication Year: 2024
Publication Date: 2024-06-16
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot